Filter
3199
Filtered Results: 3199
Text search:
U.S.
Department
of
Health
and
Human
Services,
Office
on
Women’s
Health
Featured
Recommendations
259
New Publications
955
Language
Document type
No document type
2027
Studies & Reports
525
Guidelines
278
Manuals
154
Strategic & Response Plan
120
Training Material
47
Fact sheets
18
Situation Updates
17
Brochures
6
Resource Platforms
4
Infographics
3
Countries / Regions
Global
121
India
120
Kenya
97
Uganda
83
South Africa
74
Nepal
72
Ethiopia
70
Sierra Leone
67
Nigeria
63
Western and Central Europe
63
Liberia
61
Myanmar / Burma
60
Malawi
56
Zambia
54
Tanzania
51
Latin America and the Carribbean
44
Philippines
43
Syria
42
Ghana
41
Bangladesh
41
Africa
39
Rwanda
31
Ukraine
30
Namibia
28
Asia
28
South Sudan
27
South–East Asia Region
26
Eastern Europe
25
Cambodia
23
Senegal
22
Indonesia
22
Botswana
22
Congo, Democratic Republic of
21
Lesotho
21
Zimbabwe
20
Mozambique
20
Haiti
19
Guinea
17
Pakistan
14
East and Southern Africa
13
Venezuela
13
USA
12
Germany
12
Eswatini/ Swaziland
12
Yemen
12
Afghanistan
11
Thailand
11
Colombia
11
Russia
11
Burkina Faso
10
West and Central Africa
10
Middle East and North Africa
10
Vietnam
10
Jordan
9
Laos
9
Brazil
8
Sri Lanka
8
Western Pacific Region
8
China
7
Sudan
7
Central African Republic
7
Cameroon
6
Somalia
6
Benin
6
Eastern Europe and Central Asia
6
Mali
5
Iraq
5
Lebanon
5
Turkey
5
Peru
5
Southern Africa
5
Tajikistan
5
Papua New Guinea
4
Palestine
4
North Macedonia
3
Bolivia
3
Chile
3
Paraguay
3
Albania
3
Moldova
3
North America
3
Malaysia
2
Argentina
2
Ecuador
2
Greece
2
Angola
2
Guatemala
2
Mexico
2
Canada
2
Timor Leste/ East Timor
2
Estonia
2
Georgia
2
Turkmenistan
2
United Kingdom
2
Spain
2
Côte d’Ivoire / Ivory Coast
1
Saudi Arabia
1
Niger
1
Chad
1
Gambia
1
Ireland
1
Switzerland
1
Hungary
1
Burundi
1
Honduras
1
Libya
1
Madagascar
1
Other region
1
Fiji
1
Bhutan
1
Poland
1
Armenia
1
Mongolia
1
Qatar
1
Bulgaria
1
Romania
1
Lithuania
1
Slovakia
1
Iran
1
Kazakhstan
1
Gabon
1
Japan
1
Denmark
1
Belgium
1
France
1
Mauritius
1
Portugal
1
Belarus
1
Latvia
1
Authors & Publishers
Publication Years
Category
Countries
1223
Clinical Guidelines
189
Public Health
173
Women & Child Health
160
Key Resources
154
Capacity Building
53
Pharmacy & Technologies
19
Toolboxes
Mental Health
272
HIV
254
Disability
185
TB
175
COVID-19
168
Planetary Health
126
Rapid Response
90
Conflict
87
AMR
87
Caregiver
77
Ebola
76
Refugee
71
Global Health Education
66
NTDs
58
Natural Hazards
56
Pharmacy
54
NCDs
36
Health Financing Toolbox
33
Specific Hazards
31
Zika
20
Polio
15
Cholera
11
Social Ethics
8
Typhoon
4
South Sudan
1
AIDSFree Case study series
This publication is made possible by the generous support of the American people through the U.S. President’... Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID) under the terms of Cooperative Agreement AID-OAA-A-14-00046.
The contents are the responsibility of AIDSFree and do not necessarily reflect the views of PEPFAR, USAID, or the U.S. Government.
interim Guidance 1 December 2020. Updated version
This document provides updated guidance on mask use in health care and community settings, ... during home care for COVID-19 cases. It is intended for policy makers, public health and infection prevention and control professionals, health care managers and health workers.
The Annex provides advice on how to manufacture non-medical masks. It is intended for those making non-medical masks at home and for mask manufacturers
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, ... mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released in 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
WHO published the first COVID-19 Strategic Response and Preparedness Plan (SPRP) on 3 February, 2020. This report highlights the main points of pro...
The far-reaching impacts of the COVID-19 pandemic underscore the critical need for evidence-informed, transparent and inclusive decision-making. Policy-makers have grappled with complex choices amid...
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on ... and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant and breastfeeding women, children and adolescents. The Global Action Plan has five strategic objectives: 1) prevention and response; 2) monitoring and surveillance; 3) research and innovation; 4) laboratory capacity; and 5) governance and enabling mechanisms.
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect ... the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect ... the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
At the end of 2023, WHO convened our first-ever annual WHO Stakeholder Review Conference for Prevention and Response to Sexual Misconduct. Aimed at joint learning ... frank discussion on challenges faced in the achieving zero tolerance for all forms of sexual misconduct by aid workers, the Conference brought together Member States, Civil Society Organizations, United Nations Agencies and Programmes, academia and media joined by WHO personnel. A set of recommendations to support all agencies are documented in the Conference Report. In addition, WHO’s Director-General hosted a social engagement segment on the evening of Day 1 to further underscore the centrality of a victim and survivor-centred approach, to celebrate progress however small, and to reaffirm commitment and renew energy for the journey ahead. The Conference took place on 30 November and 1 December 2023 in Geneva, Switzerland
This annual report highlights the work of the WHO from January to June 2021 ( December 2021). The activities featured herein are by no means exhausted but implemented with technical and financial su...
About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% ... those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s immunological status. TB preventive treatment (TPT) given to people at highest risk of progressing from TB infection to disease remains a critical element to achieve the global targets of the End TB Strategy, as reiterated by the second UN High Level Meeting on TB in 2023. Delivering TPT effectively and safely necessitates a programmatic approach to implement a comprehensive package of interventions along a cascade of care: identifying individuals at highest risk, screening for TB and ruling out TB disease, testing for TB infection, and choosing the preventive treatment option that is best suited to an individual, managing adverse events, supporting medication adherence and monitoring programmatic performance.
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO ... in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), National Institutes of Health/National Institute of Allergy and Infectious Diseases(NIH/NIAID), Long Covid SOS and patient representatives.
Operational guide: use of referral laboratories for the analysis of foodborne hazards in the Pacific
The Operational guide: use of referral laboratories for the analysis of foodborne hazards in the Pacific aims to strengthen the food analysis capacity of<...
The ninth WHO report on the global tobacco epidemic tracks the progress made by countries in tobacco control since 2008 and, marks 15 years since the introduction ... the MPOWER technical package which is designed to help countries implement the demand-reduction measures of the WHO Framework Convention on Tobacco Control. The report shows that many countries continue to make progress in the fight against tobacco, but efforts must be accelerated to protect people from the harms of tobacco and second-hand smoke.
Reducing the humanitarian impact of the use of explosive weapons in populated areas is a key priority for the United
Nations, the International Committee ... the Red Cross (ICRC), civil society and an increasing number of Member States.
The United Nations Secretary-General has expressly called on parties to conflict to avoid the use in populated areas of
explosive weapons with wide-area effects.
While the use of explosive weapons in populated areas may in some circumstances be lawful under international
humanitarian law (IHL), empirical evidence reveals a foreseeable and often widespread pattern of harm to civilians,
particularly from explosive weapons with wide-area effects.
Many types of explosive weapons exist and are currently in use. These include air-delivered bombs, artillery projectiles,
missiles and rockets, mortar bombs, and improvised explosive devices (IEDs). Some are launched from the air and
others are surface launched. Whilst different technical features dictate their accuracy of delivery and explosive effect,
these weapons generally create a zone of blast and fragmentation with the potential to kill, injure or damage anyone
or anything within that zone. This makes their use in populated areas – such as towns, cities, markets and camps for
refugees and displaced persons or other concentrations of civilians – particularly problematic. The problems increase
further if the effects of the weapon extend across a wide-area either because of the scale of blast that they produce; their
inaccuracy; the use of multiple munitions across an area; or a combination thereof.
The Interim Guidance for Risk Communication and Community Engagement (RCCE) outlines recommendations, considerations and methods to raise awareness, manage risk perception, maintain trust ... proactively support people at risk to make informed decisions to protect themselves and others from monkeypox. The guidance includes recommendations on identifying and communicating with affected populations and key audiences and avoiding stigma in communications outreach. It also includes key messages about symptoms of monkeypox, transmission, prevention measures, and communicating about uncertainty. This document also provides RCCE guidance for managers and planners of gatherings and events, where close physical contact may create an environment conducive for the transmission of monkeypox. Additionally, this document includes a compendium of recommendations for RCCE methods and resources to support the monkeypox response.
Global Report on assistive technology
recommended
The report notes that the number of people in need of one or more assistive products is likely to rise to 3.5 billion by 2050, due to populations ageing a... the prevalence of noncommunicable diseases rising across the world. The report also highlights the vast gap in access between low- and high-income countries. An analysis of 35 countries reveals that access varies from 3% in poorer nations to 90% in wealthy countries.
Affordability is a major barrier to access, the report notes. Around two thirds of people with assistive products reported out-of-pocket payments for them. Others reported relying on family and friends to financially support their needs.
Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance ... the methodology to be used for assessing, at field level, the yellow fever virus circulation in areas at risk, and is primarily intended for public health specialists
Over the reporting period, economic actors continued to carry out their activities with little regard for their impacts on the livelihoods of the communities living in the surrounding areas. In Doo ...
2nd edition - Published in 2003, the first WHO/HAI medicine prices manual Medicine Prices – A
New Approach to Measurement Draft for field-testing provides a draft methodology and tools to conduct national medicine prices ... availability surveys. This second edition of the survey manual has been updated to reflect the wealth of practical
experience in conducting medicine prices and availability surveys garnered in the project’s first two phases.
